AgeX Therapeutics

AgeX is a biotechnology company dedicated to developing novel therapies for age-related degenerative diseases. AgeX's mission is to apply proprietary technology platforms related to telomerase-mediated cellular immortality and regenerative biology to address various aging-related conditions. Current preclinical development efforts include two cell-based therapies derived from telomerase-positive pluripotent stem cells, as well as two candidate products originating from the company’s proprietary induced Tissue Regeneration (iTR™) technology.AGEX-BAT1 and AGEX-VASC1 are cell-based approaches in preclinical development, consisting of young regenerative cells modified using AgeX’s UniverCyte™ technology to promote immune tolerance and formulated with HyStem® matrix, designed to correct metabolic imbalances in aging and restore vascular support to ischemic tissues, respectively. AGEX-iTR1547 is a drug-based formulation in preclinical development aimed at restoring the regenerative potential of aged tissues affected by degenerative diseases using the company’s proprietary iTR technology.